NeuroDerm Ltd. Ordinary Shares
NDRM
NDRM was delisted on the 17th of October, 2017.
15 hedge funds and large institutions have $20.7M invested in NeuroDerm Ltd. Ordinary Shares in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.93M |
| 2 |
PA
Perceptive Advisors
New York
|
+$2.77M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$1.98M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$381K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$125K |
Top Sellers
NDRM Hedge Fund Activity: Q4 2014 in Review
15 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in NeuroDerm Ltd. Ordinary Shares (NDRM) for Q4 2014, worth a combined $20.7M.
Buyers outnumbered sellers: 15 funds opened new NDRM positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $5.93M.
- 15 institutional investors held NeuroDerm Ltd. Ordinary Shares (NDRM) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $20.7M of NeuroDerm Ltd. Ordinary Shares stock for Q4 2014.
- 15 funds opened new NeuroDerm Ltd. Ordinary Shares positions in Q4 2014 and 0 closed out, a net change of +15 holders.
- The largest NeuroDerm Ltd. Ordinary Shares buyer in Q4 2014 was Adage Capital Partners, an estimated $5.93M added.
Based on aggregated 13F filings for Q4 2014.